Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

What Is The Present And Forecasted Size Of The Parkinson’s Disease Market?

The market size for Parkinson’s disease has seen significant expansion in the recent past. The predicted increase is from $3.34 billion in 2024 to $3.62 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 8.2%. Factors contributing to this expansion during the historical period include amplified research and development, increased government funding, enhancement in customized treatment modalities, development in support structures for those affected by Parkinson’s disease, and a rise in the utilization of progressive rehabilitation therapies.

Expectations for the Parkinson’s disease market size predict robust expansion in the ensuing years, swelling to approximately $4.94 billion by 2029. This pertains to a compound annual growth rate (CAGR) of 8.1%. The projected growth within the forecast period can be credited to an increase in the understanding of Parkinson’s disease symptoms, amplified government interventions, expansion in healthcare expenditure, growth in the frequency of Parkinson’s disease clinical trials, and increased acceptance of gene therapies. Significant trends in the forecast period involve technological progressions, government interventions and funding, application of artificial intelligence in diagnosis, inventive solutions, and tailor-made medicine.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21247&type=smp

What Underlying Factors Are Supporting The Parkinson’s Disease Market Growth?

The escalating occurrence of neurodegenerative conditions is anticipated to drive the expansion of the parkinson’s disease market in the future. Neurodegenerative diseases encompass a range of disorders marked by the gradual degeneration and functional loss of neurons in the brain and nervous system. The growing incidence of these conditions can be attributed to factors like an aging populace, genetic susceptibility, environmental factors, improved diagnostic methods, increasing chronic health issues, and shifts in lifestyle. Parkinson’s disease contributes to the comprehension of neurodegenerative diseases by offering essential insights into their fundamental mechanisms, potential treatment targets, and the creation of innovative therapy strategies. For instance, the European Brain Council, a Belgium-based non-profit, reported in April 2022 that over 600 neurological diseases and almost 300 psychiatric conditions affect millions worldwide, including 65 million people with epilepsy. In Europe, dementia affects 10.5 million individuals, with estimates suggesting a surge to 18.7 million by 2050. Thus, the escalating occurrence of neurodegenerative diseases is propelling the expansion of the parkinson’s disease market.

How Does The Parkinson’s Disease Market Differ By Segment?

The parkinson’s diseasemarket covered in this report is segmented –

1) By Drug Class: Dopamine Agonists; Catechol-O-Methyltransferase Inhibitors; Monoamine Oxidase B Inhibitors; Anticholinergics; Carbidopa-Levodopa; Other Drug Classes

2) By Route Of Administration: Oral; Injectable; Intestinal infusion; Subcutaneous; Other Route Of Administrations

3) By Distribution Channel: Retail Pharmacies; Hospital Pharmacies; Online Pharmacies

4) By Patient Care Setting: Clinics; Hospitals

Subsegments:

1) By Dopamine Agonists: Ergot Derivatives; Non-Ergot Derivatives

2) By Catechol-O-Methyltransferase (COMT) Inhibitors: Entacapone; Tolcapone; Opicapone

3) By Monoamine Oxidase B (MAO-B) Inhibitors: Selegiline; Rasagiline; Safinamide

4) By Anticholinergics: Trihexyphenidyl; Benztropine; Procyclidine

5) By Carbidopa-Levodopa: Immediate-Release Formulation; Extended-Release Formulation; Inhaled And Intestinal Gel Formulations

6) By Other Drug Classes: Amantadine And Derivatives; Adenosine A2A Receptor Antagonists; Glutamate Antagonists

What Are The Dominant Trends Currently Seen In The Parkinson’s Disease Market?

Major companies in the Parkinson’s disease market are concentrating on creating innovative treatments like levodopa-based therapies to enhance motor function and provide ongoing symptom control for patients with advanced Parkinson’s disease. Levodopa-based therapy uses levodopa, which converts to dopamine in the brain, to improve motor abilities and ease Parkinson’s symptoms. For example, in October 2024, AbbVie Inc., a U.S.-based biopharmaceutical firm, obtained FDA approval for VYALEV, a combination therapy of levodopa and carbidopa developed to treat Parkinson’s disease. This formulation aims to boost levodopa’s effectiveness by preventing its breakdown before it reaches the brain, thereby raising dopamine levels. It effectively manages motor symptoms such as tremors, rigidity, and bradykinesia, ultimately helping patients perform daily activities better. This therapy is recognized as an essential option for patients experiencing motor fluctuations.

Who Are The Global Leaders Steering The Parkinson’s Disease Market Forward?

Major companies operating in the parkinson’s disease market are Roche Holding AG, AbbVie Inc., Novo Nordisk A/S, Takeda Pharmaceutical Company Limited, UCB S.A., Eisai Co. Ltd., Kyowa Kirin Co. Ltd., Amneal Pharmaceuticals Inc., Neurocrine Biosciences Inc., Supernus Pharmaceuticals Inc., Sunovion Pharmaceuticals Inc., Intracellular Therapies Inc., Voyager Therapeutics Inc., Sage Therapeutics Inc., Adamas Pharmaceuticals Inc., Sun Pharma Advanced Research Company Ltd., Neuraly Inc., Mitsubishi Tanabe Pharma Corporation, Athira Pharma Inc., VistaGen Therapeutics Inc.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/parkinsons-disease-global-market-report

Which Region Is Likely To Register The Fastest Growth In The Parkinson’s Disease Market?

North America was the largest region in the parkinson’s disease market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the parkinson’s disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=21247&type=smp

Browse Through More Reports Similar to the Global Parkinson’s Disease Market 2025, By The Business Research Company

Autoimmune Disease Diagnosis Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/autoimmune-disease-diagnosis-global-market-report

Alzheimer Disease Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/alzheimer-disease-treatment-global-market-report

Chronic Disease Management Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/chronic-disease-management-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model